Cuprina Holdings (Cayman) Limited Class A (CUPR)
NASDAQ:CUPR
Want to see CUPR full AI Analyst Report?
CUPR Stock Chart & Stats
$0.38
--
Market closed
$0.38
--
Day’s Range― - ―
52-Week Range$1.76 - $76.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.90M
Market Cap
$4.02M
Enterprise Value$7.89M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.05
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding920,625
10 Day Avg. Volume197,362
30 Day Avg. Volume2,899,437
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.08
Price to Sales (P/S)211.01
P/FCF Ratio-1.15
Enterprise Value/Market Cap1.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA 510(k) ClearanceThe FDA 510(k) clearance is a durable regulatory milestone that creates a U.S. commercial pathway and a global benchmark for the product. It supports sustainable revenue potential in chronic wound care, strengthens clinician acceptance, and lowers regulatory risk for future market expansions.
Nasdaq Compliance RestoredRestoring Nasdaq compliance removes immediate listing risk and preserves access to U.S. capital markets. That structural outcome sustains the company's ability to raise equity or debt, maintain liquidity for operations, and pursue strategic partnerships without disruption from delisting.
Dual-species Product PlatformControl of both maggot species creates a differentiated, adaptable product platform that can be tailored by region and clinician preference. This breadth strengthens competitive position in wound care, supports multiple regulatory filings, and raises barriers to entry for niche competitors.
Bears Say
Negative Cash Flow TrendPersistent negative operating and free cash flow, with a marked increase in 2025 burn, signals structural funding reliance. Without sustained revenue improvements or cost reduction, the company will need repeated external financing, raising dilution risk and limiting long-term operational autonomy.
Deteriorating ProfitabilityThe shift to negative gross profit and widening losses in 2025 indicates weak margin sustainability and poor operating leverage. Until the company achieves consistent higher-margin sales or structural cost cuts, profitability remains elusive and constrains reinvestment capacity.
Entrenched Governance & Capital FlexibilityThe capital overhaul sharply increases Class B control and expands authorized capital, structurally tilting governance. That entrenched control plus broad issuance flexibility raises minority shareholder risk and makes future equity raises potentially dilutive or controlled by dominant holders.
Cuprina Holdings (Cayman) Limited Class A News
CUPR FAQ
What was Cuprina Holdings (Cayman) Limited Class A’s price range in the past 12 months?
Cuprina Holdings (Cayman) Limited Class A lowest stock price was $1.76 and its highest was $76.00 in the past 12 months.
What is Cuprina Holdings (Cayman) Limited Class A’s market cap?
Cuprina Holdings (Cayman) Limited Class A’s market cap is $4.02M.
When is Cuprina Holdings (Cayman) Limited Class A’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cuprina Holdings (Cayman) Limited Class A’s earnings last quarter?
Currently, no data Available
Is Cuprina Holdings (Cayman) Limited Class A overvalued?
According to Wall Street analysts Cuprina Holdings (Cayman) Limited Class A’s price is currently Overvalued.
Does Cuprina Holdings (Cayman) Limited Class A pay dividends?
Cuprina Holdings (Cayman) Limited Class A does not currently pay dividends.
What is Cuprina Holdings (Cayman) Limited Class A’s EPS estimate?
Cuprina Holdings (Cayman) Limited Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cuprina Holdings (Cayman) Limited Class A have?
Cuprina Holdings (Cayman) Limited Class A has 920,625 shares outstanding.
What happened to Cuprina Holdings (Cayman) Limited Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cuprina Holdings (Cayman) Limited Class A?
Currently, no hedge funds are holding shares in CUPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cuprina Holdings (Cayman) Limited Class A
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
Technical Analysis
GeoVax Labs
―
HCW Biologics
―
Calidi Biotherapeutics
―
Psyence Biomedical
―
Aspire Biopharma Holdings
―
Ownership Overview
―
Insiders
0.17% Mutual Funds
― Other Institutional Investors
99.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---